BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Randox Services Pushes the Boundaries of Biomarker Discovery


5/10/2011 11:14:20 AM

Crumlin, UK, 10th May 2011 -- Randox has been supplying the world’s leading CRO’s, Pharmaceutical and Biotech companies for nearly three decades, and has unrivalled in-house technical know-how, whether in the development of new biomarker assays, companion diagnostics or the manufacture of the highest quality clinical diagnostic reagents.

Despite already supplying over 400 biomarker assays from their current product portfolio, Randox Pharma Services are investing to develop solutions for biomarker discovery, given their broad range of applications from the diagnosis, prognosis and monitoring of disease progression through to the monitoring of clinical responses to a therapeutic intervention and personalised medicine.

Currently biomarker discovery by mass spectrometry is an expensive and laborious method, with limitations in reproducibility and sensitivity due to the wide range of protein concentrations in plasma and extensive processing requirements. Biomarker validation and follow-on studies can also be impeded by a lack of available immuno-affinity reagents.

In response to these limitations, the recently developed QuantiPlasma Array from Randox is a monoclonal antibody microarray designed to assess the level of multiple proteins simultaneously in human plasma. Each kit contains 300 unique monoclonal antibodies, so by using the QuantiPlasma Array it is possible to directly assess the plasma proteome dynamics of normal and disease state plasma samples for identification of novel biomarkers in conjunction with Randox’s Biochip Array Technology analyser platform.

With such innovative solutions Randox Pharma Services is working to help meet the pressing need for biomarker discovery in a cost effective manner and ultimately enable their translation to new diagnostic solutions and improved healthcare.

For more information please visit www.randoxpharmaservices.com or email pharmaservices@randox.com.

About Randox Pharma Services

In recognition of the vital role biomarkers play in drug development programmes, Randox Pharma Services offer a comprehensive range of solutions, allowing Pharma R&D to become more efficient, cost effective and safer. Biochip Array Technology, a revolutionary multiplexing technology, enables multiple biomarker results from a single sample. Over 120 enzymatic, substrate and immunoturbidimetric assays are available for use on our range of world class clinical chemistry analysers while our QC range provides essential performance checks and traceability. We can even provide a tailor made solution to fulfil your requirements. Randox Pharma Services support every stage of the clinical trial process.



Read at BioSpace.com

Randox
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES